Isatuximab
( DrugBank: Isatuximab / KEGG DRUG: Isatuximab )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 28 | Systemic amyloidosis | 4 |
| 61 | Autoimmune hemolytic anemia | 6 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 283 | Acquired pure red cell aplasia | 1 |
28. Systemic amyloidosis
Clinical trials : 335 / Drugs : 274 - (DrugBank : 86) / Drug target genes : 47 - Drug target pathways : 165
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
61. Autoimmune hemolytic anemia
Clinical trials : 183 / Drugs : 119 - (DrugBank : 42) / Drug target genes : 31 - Drug target pathways : 156
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
283. Acquired pure red cell aplasia
Clinical trials : 21 / Drugs : 35 - (DrugBank : 20) / Drug target genes : 27 - Drug target pathways : 110
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|